Document Detail

Evaluation and management of adnexal masses during pregnancy.
MedLine Citation:
PMID:  16885656     Owner:  NLM     Status:  MEDLINE    
An increase in the incidence of adnexal masses uncovered during pregnancy has occurred concurrently with the adoption of near universal use of prenatal ultrasound. The majority of these masses resolve by the second trimester. Persistent masses continue to be at risk for significant sequelae such as torsion, rupture, and obstruction of labor. These events may result in the need for emergent surgical intervention with increased risk of adverse outcome for both mother and fetus. In addition a small risk of cancer exists and extended delay in diagnosis should be avoided. As such, surgical excision of persistent adnexal masses should be entertained at approximately 16 to 20 weeks of gestation. In the approximately 5% of cases in which an adnexal masses proves to be a malignancy, appropriate staging may be safely performed. In selected cases, chemotherapy should at least be entertained.
Robert L Giuntoli; Russell S Vang; Robert E Bristow
Related Documents :
18946936 - Management and outcomes of adnexal masses during pregnancy: a 6-year experience.
23577786 - Outcome following selective fetal reduction in monochorionic and dichorionic twin pregn...
23369936 - Significance of growth discordance in appropriately grown twins.
10411786 - Adnexal masses in pregnancy: a review of 130 cases undergoing surgical management.
1348806 - Clinical study of the lactational amenorrhoea method for family planning.
12848286 - High-dha eggs: feasibility as a means to enhance circulating dha in mother and infant.
Publication Detail:
Type:  Journal Article; Review    
Journal Detail:
Title:  Clinical obstetrics and gynecology     Volume:  49     ISSN:  0009-9201     ISO Abbreviation:  Clin Obstet Gynecol     Publication Date:  2006 Sep 
Date Detail:
Created Date:  2006-08-03     Completed Date:  2006-10-27     Revised Date:  2009-11-11    
Medline Journal Info:
Nlm Unique ID:  0070014     Medline TA:  Clin Obstet Gynecol     Country:  United States    
Other Details:
Languages:  eng     Pagination:  492-505     Citation Subset:  IM    
Hopkins Medical Institutions, Phipps 281, Baltimore, Maryland 21287, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
CA-125 Antigen / blood
Chemotherapy, Adjuvant
Neoplasm Staging
Ovarian Neoplasms / diagnosis*,  epidemiology,  therapy*
Pregnancy Complications, Neoplastic / diagnosis*,  epidemiology,  therapy*
Reg. No./Substance:
0/CA-125 Antigen

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Management of ovarian endometrioma.
Next Document:  The incidental postmenopausal adnexal mass.